News

These results may support clinical decision-making for psoriasis and nail psoriasis management and may allow future real-world studies to further understand the nature of this skin disease.

A study showed tildrakizumab treated difficult-to-treat psoriasis areas in patients who failed anti-IL17 treatment.

The CRL for the sBLA cites a lack of sufficient data to support the full evaluation of the effectiveness and safety of a 4-dose regimen in this patient population.

Further analyses into the 2-year PROTECT trial further support the longevity of benefit with sparsentan in patients with IgAN.

The multicenter study examined the presentation and outcomes of patients with cirrhosis-related IgAN and compared clinicopathological profiles with primary IgAN.

The treatment, made up of clindamycin phosphate, adapalene, and benzoyl peroxide, led to clear or almost clear skin among a significant number of individuals with acne.

Oldham highlights the anticipated change to a more dimensional perspective on personality disorders in new guidelines anticipated later this year.

In an interview, King provided an overview of the history of psychedelic research for psychiatric conditions, where we are now, and what hurdles investigators must address.

Boehringer Ingelheim expands access to adalimumab biosimilar adalimumab-adbm through agreement with Quallent Pharmaceuticals,

Announced by Sanofi on May 10, 2024, the updated FDA label is based on full results from the pivotal phase 3 XTEND-Kids study.

In this interview segment, Rigotti discussed the way in which cytisinicline can help adults to quit e-cigarettes and the future of her team’s research on this product.

At the end of ARVO 2024, Srinivas R. Sadda, MD, became the organization's president for the 2024-2025 year. He spoke to HCPLive about his expectations for the next year in eye care.

The SEQUOIA-HCM trial presents aficamten as a promising treatment for symptomatic obstructive hypertrophic cardiomyopathy, showing significant improvements in multiple endpoints.

Nieca Goldberg, MD, discusses important news and updates in cardiovascular health among women from the early portions of 2024.

The analysis of NHANES data revealed almost 90% of adults meet the criteria for stage 1 or greater CKM syndrome, consistent from 2011-2020.

Sibille and colleagues have made progress in refining the therapeutic pathways of Alzheimer disease. Human trials may soon follow.

Factors, including social deprivation and race, significantly affected visit adherence for patients with nAMD across a large healthcare system.

This discussion covered the topic of e-cigarette use and its potential treatment with cytisinicline, a plant-based medication which may aid vapers in quitting.

Phillips emphasizes the importance of screening for obsessive-compulsive disorders, such as OCD, body dysmorphic disorder, and trichillomania.

A novel score based on a combination of cytokeratins and routine laboratory tests provided a more accurate diagnosis of HCC versus serum α-fetoprotein alone.

At ARVO 2024, Nazlee Zebardast, MD, MSc describes the value of a polygenic risk score to predict the onset of primary open-angle glaucoma.

The tool’s development for scoring severity among complex nail psoriasis cases and monitoring response to treatment may allow for improved outcomes among patients.

In an interview with HCPLive, Jha said clinicians should think of interventional approaches for treatment-resistant depression “sooner rather than later.”

McIntyre discusses how GLP-1 and GIP receptor agonists like semaglutide could potentially improve both acute and long-term measures of psychiatric disease.

Glecaprevir/pibrentasvir is an effective treatment for HCV with high rates of SVR, even in patients with cirrhosis undergoing a shorter treatment regimen.

A Veterans Affairs study finds low alpha-1 antitrypsin phenotyping rates, indicating the need for improved healthcare provider education on AATD.

In an interview, Phillip explained the difference between OCD and body dysmorphic disorder, even though they are grouped in the DSM-5.

A higher dietary intake of several nutrients was strongly associated with slower progression toward the central macula in eyes with non-central GA.